Updated Feb. 15, 2013 at 6:58 a.m.

Premium Lock Targacept's 4Q loss widens to $15.9M

Published: 2013-02-14 15:44:00
Updated: 2013-02-15 06:58:15

Print this blog post
Targacept

The restructuring, which trimmed Targacept's headcount nearly in half, followed the failure of the Winston-Salem company's lead drug -- a depression treatment -- in phase III clinical trials. The company has refocused its efforts on its remaining compounds in phase II studies.

Targacept reported just $590,000 in fourth quarter revenue, down from $18.9 million a year ago. Although Targacept has no Food and Drug Administration-approved drugs, the company drew revenue from alliances with larger drug companies, who helped finance drug development work. The steep revenue drop is linked to Targacept's loss of partnerships with GlaxoSmithKline (NYSE: GSK) and AstraZeneca (NYSE: AZN). The GSK partnership ended in 2011. AstraZeneca had collaborated with Targacept on the experimental depression treatment. But shortly after that compound failed in phase III  trials last winter, that partnership terminated as well. AstraZeneca remains a partner with Targacept on other compounds.

Targacept's restructuring charges for the fourth quarter were $1.4 million. For the year the company reported $3.7 million in restructuring charges.

 

...

WRAL Tech Wire any time: Twitter, Facebook

Copyright 2013 WRAL Tech Wire. All rights reserved.

Please log in or register to view WRALTechWire Insider content


To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.

 1 Year Membership - 49.99 per year. Includes FREE unlimited access to online content, archives and discounts from Insider Partners. For less than $1 a week receive more than $900 in value.

 Monthly Membership - 4.99 per month. Includes FREE unlimited access every 30 days to online content only.

 Day Pass - 0.99 per day. Includes FREE unlimited access for 24 hours to online content only.

Editor's Blog

Editor's Blog

The latest blog posts from our WRAL Tech Wire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Jim Roberts
Entrepreneurship
Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Scroll